Stock Events

Stock Events

TrovaGene 

0
79
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2026
Q2 2026
Next
-0.15
-0.14
-0.12
-0.1
Expected EPS
-0.11867061139999999
Actual EPS
N/A

Financials

-7,802.97%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
512,745.45Revenue
-40.01MNet Income

Analyst Ratings

1.52Average Price Target
The highest estimate is 1.52.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XE7B.STU. It's not an investment recommendation.
Microsoft
16
MSFT
NVIDIA
16
NVDA
Apple
15
AAPL
Tesla
15
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including targeted therapies and immunotherapies that compete across multiple areas of cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers a wide range of cancer treatments, including targeted therapies and immunotherapies, directly competing with Cardiff Oncology's approach to cancer treatment.
Merck
MRK
Mkt Cap366B
Merck is known for its strong oncology pipeline, including blockbuster cancer drug Keytruda, competing in the space of innovative cancer therapies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse oncology portfolio, including treatments for solid tumors and hematologic malignancies, making it a competitor in the broader oncology market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma, has become a leader in cell therapy for cancer, competing in the innovative treatment space alongside Cardiff Oncology.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio, including targeted therapies and immunotherapies, competing in various cancer treatment areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, with its acquisition of Pharmacyclics, has strengthened its oncology portfolio, competing in the space of cancer treatment with a focus on hematologic malignancies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its innovative biologics, competes in the oncology space with treatments that could potentially overlap with Cardiff Oncology's target patient populations.

About

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Show more...
CEO
Mani Mohindru
Employees
31
Country
United States
ISIN
US8972386069
WKN
000A2P4GU

Listings

STU
DE
XE7C.STU
STU
DE
XE7B.STU
MU
DE
XE7C.MU
XNAS
US
CRDF

0 Comments

Share your thoughts

FAQ

What is TrovaGene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange TrovaGene stocks are traded under the ticker XE7B.STU.
When is the next TrovaGene earnings date?▼
TrovaGene is going to release the next earnings report on October 29, 2026.
What were TrovaGene earnings last quarter?▼
XE7B.STU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.1 EUR resulting in a -17.02% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is TrovaGene revenue for the last year?▼
TrovaGene revenue for the last year amounts to 512,745.45 EUR.
What is TrovaGene net income for the last year?▼
XE7B.STU net income for the last year is -40.01M EUR.
How many employees does TrovaGene have?▼
As of September 04, 2026, the company has 31 employees.
In which sector is TrovaGene located?▼
TrovaGene operates in the Health & Wellness sector.
When did TrovaGene complete a stock split?▼
TrovaGene has not had any recent stock splits.
Where is TrovaGene headquartered?▼
TrovaGene is headquartered in SAN DIEGO, United States.